23 January 2024
23 January 2024
Cohort B of the trial included 108 participants with scalp predominant moderate-to-severe PsO.
The trial aims to enrol 532 subjects with HR+ and HER2-low metastatic breast cancer.
Prilenia has announced plans to initiate a Phase III trial in H2 2024 after presenting results at the Annual California ALS Research Summit in Los Angeles, US.
Preclinical data suggest that STX-001 could overcome the limitations of current immunotherapy options.
The drug was found to be well-tolerated, with a safety profile matching that reported in previous trials.
Adding to prior European Innovation Council investment, the funds will help the start-up’s goal of US market access by 2025.
While Opdivo will likely face fierce competition, it is the first treatment to demonstrate clinically relevant data with a control arm.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
